Neratinib ( Nerlynx® (brand name); Neratinib (generic name) )

Targeted Therapy

Not submitted to EMA

Not funded 3 Clinical Trials

Description

Neratinib is used in the extended adjuvant setting for patients with early-stage HER2-positive breast cancer following trastuzumab-based therapy. It has not been approved or widely studied for use in colorectal cancer (CRC).

Mechanism of Action

Neratinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor that blocks the activity of EGFR (ErbB1) and other ErbB family members, including HER2.

Side Effects

Diarrhea; Nausea; Vomiting; Fatigue; Skin rash; Elevated liver enzymes;

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03919292 Phase 1

Recruiting

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

United States

NCT06519110 Phase 2

Not yet recruiting

Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations

NCT03065387 Phase 1

Active, not recruiting

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

United States

Quick Info

Brand Name	Nerlynx® (brand name); Neratinib (generic name)
Category	Targeted Therapy
EMA Status	Not submitted to EMA
Spain Access	Not funded
Clinical Trials	3

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.

Neratinib (** Nerlynx® (brand name); Neratinib (generic name) **)